Borderline Ovarian Epithelial Tumor

A borderline ovarian epithelial tumour is an abnormal growth that starts in the thin surface layer of the ovary. Doctors call that layer the “epithelium.” The growth has more cells, more crowding, and more complex patterns than a harmless cyst. But it does not invade and destroy nearby tissue the way cancer does. That is why it is called “borderline.” It sits between benign (harmless) cysts and invasive cancer. Many people do very well with surgery alone. Survival is excellent, especially when the tumour is found early and kept inside the ovary. Cancer.gov

A borderline ovarian epithelial tumor (also called “tumor of low malignant potential”) is a growth that starts on the surface lining of the ovary. Under the microscope, the cells look abnormal and proliferative, but—by definition—they do not invade nearby tissues the way cancer does. BOTs grow more slowly, are usually diagnosed earlier than ovarian cancer, and have an excellent long-term outlook, especially when completely removed by surgery. Five-, 10-, and 20-year survival rates are commonly above 90% when managed appropriately, and chemotherapy is usually not needed unless there is advanced spread or malignant transformation. Cancer.gov+2Cancer.gov+2

Borderline tumours are part of the modern World Health Organization (WHO) system for ovarian tumours. “Borderline” is the preferred word. Older terms like “low malignant potential (LMP)” and “atypical proliferative” appear in older books and on some websites, but WHO now uses “borderline” for clarity. ICCR

Other names

You may see these labels in reports or on health sites. They usually point to the same family of tumours:

• Borderline ovarian tumour (BOT)

• Borderline epithelial ovarian tumour

• Ovarian tumour of low malignant potential (LMP) — older term

• Atypical proliferative ovarian tumour — older term

• Type by cell pattern, for example: serous borderline tumour, mucinous borderline tumour, endometrioid borderline tumour, clear cell borderline tumour, seromucinous borderline tumour, and Brenner (transitional) borderline tumour. These names tell us how the tumour looks under the microscope. ICCR+1

Types

Pathologists (the lab doctors) group borderline tumours by their cell pattern. This helps with treatment choices and follow-up.

1. Serous borderline tumour (SBT)
   This is the most common type. It often shows tiny finger-like parts (papillae) and special cell changes like BRAF or KRAS pathway activation in many cases. Some SBTs have tiny outgrowths outside the ovary called “implants.” Most implants are non-invasive and still have a very good outlook. Cancer.gov+1

2. Mucinous borderline tumour (MBT)
   Cells make mucus. There are two broad patterns: intestinal type and endocervical/seromucinous type. Some MBTs contain spots of “intraepithelial carcinoma,” which means worrisome changes on the surface without invasion. True invasion changes the diagnosis to cancer. PMC+1

3. Endometrioid borderline tumour
   Less common. Linked to endometriosis in some patients. It behaves better than invasive endometrioid cancer. PubMed

4. Seromucinous borderline tumour
   Mixed features that look a bit like endocervical glands. WHO uses “seromucinous” as the name. Older reports sometimes used other labels for the same look. ICCR

5. Clear cell borderline tumour
   Very rare. Cells look clear or “hobnail.” It is still considered a borderline pattern if it does not invade. AJR Online

6. Brenner (transitional) borderline tumour
   Very rare. Cells look like those that line parts of the urinary tract. Most Brenner tumours are benign; borderline cases sit in the middle. ICCR

Causes and risk factors

No single cause explains all borderline tumours. Risk comes from a mix of life events, hormones, and cell changes. These points are based on large reviews and expert guidelines about ovarian epithelial tumours and borderline tumours. Cancer.gov+2PubMed+2

1. Ovulation over many years
   More ovulations may raise risk over time. Pregnancy, breastfeeding, and birth-control pills lower ovulation and can reduce risk for epithelial ovarian tumours overall.

2. Endometriosis
   Endometriosis is linked to some borderline subtypes (especially endometrioid and seromucinous patterns). The link is stronger for endometrioid and clear cell epithelial tumours in general. PubMed

3. Family history of ovarian or related cancers
   A strong family history raises concern, though borderline tumours are less tied to BRCA genes than high-grade serous cancer. Genetic counselling can help decide on testing. Cancer.gov

4. Hormone exposure across life
   Long lifetime estrogen exposure without breaks may increase general epithelial ovarian risk; pregnancy and combined pills may lower it. Cancer.gov

5. Smoking (especially for mucinous type)
   Smoking is linked to mucinous epithelial tumours, and many mucinous borderline tumours share pathways with them. PubMed

6. Certain gene changes in the tumour (not inherited)
   Borderline tumours often show KRAS or BRAF pathway changes (especially serous and mucinous types). These are changes in the tumour, not always inherited. Cancer.gov+1

7. Endocrine conditions that change ovulation
   Problems that cause fewer or more irregular ovulations may change risk patterns across epithelial tumours in general. Evidence varies. Cancer.gov

8. Pelvic inflammation across time
   Chronic irritation and repair cycles may play a role in epithelial tumours; firm links with borderline tumours are still being studied. PubMed

9. Age
   Borderline tumours are often found a bit younger than invasive ovarian cancers. Many patients are in their 30s or 40s, but any adult can be affected. Cancer.gov

10. Prior ovarian cysts
    Most cysts are harmless. A complex or persistent cyst may sometimes turn out to be borderline on surgical pathology. RCOG+1

11. Infertility history
    Infertility overlaps with many ovarian conditions. Untangling cause from effect is hard. Risk from fertility drugs alone is still debated. Cancer.gov

12. Body weight
    High body weight changes hormone levels and is linked to several female cancers. Data for borderline tumours are mixed, but weight control is good for overall health. Cancer.gov

13. Early first period or late menopause
    More ovulatory years may raise risk for epithelial tumours as a group. Cancer.gov

14. Never carrying a pregnancy
    Fewer breaks from ovulation may raise general epithelial ovarian risk. Cancer.gov

15. No long-term use of oral contraceptives
    Pills lower risk for epithelial ovarian tumours. Not using them does not “cause” a tumour, but the absence of this protection may matter. Cancer.gov

16. Prior pelvic surgery with tissue implants
    Very rare case reports describe endometriosis or mucinous tissue spreading after surgery and later forming tumours. This is uncommon. PMC

17. Borderline tumour in the other ovary (past)
    Having had a BOT before raises the chance of a new ovarian mass later, so careful follow-up is wise. Cancer.gov

18. Serous implants in the abdomen (non-invasive)
    These are outgrowths related to serous borderline tumours. They need expert surgical staging and long follow-up but still have good outcomes when non-invasive. Cancer.gov

19. Environmental factors (under study)
    Links with talc and other exposures are studied for epithelial tumours in general; firm proof for borderline tumours is limited. Cancer.gov

20. Random cell changes with age
    Some tumours happen without clear risk factors. Many patients have no known cause. Cancer.gov

Symptoms

Many people have no symptoms early. Symptoms can be vague and come from a growing mass or fluid.

1. Lower tummy (pelvic) pain or pressure — common first sign.

2. Bloating or swelling — clothes feel tighter.

3. A feeling of fullness very fast when eating — early satiety.

4. Frequent urination — pressure on the bladder.

5. Constipation or bowel changes — pressure on the bowel.

6. Back or hip ache — from pull or weight of a large cyst.

7. Irregular bleeding — spotting or cycle change, less common but possible.

8. Pain with sex — deep pelvic pressure.

9. Nausea or indigestion — from pressure or slow bowel.

10. A lump you or your doctor can feel — on exam.

11. Abdominal fluid (ascites) — belly looks full; usually with advanced spread.

12. Shortness of breath — rare; can occur if fluid reaches the chest.

13. Unplanned weight loss or fatigue — less common in borderline than in invasive cancer.

14. Fertility trouble — sometimes the first reason a cyst is found.

15. No symptoms at all — found by chance on scan or during surgery. Cancer.gov+1

Diagnostic tests

Important note: There is no single blood test that proves a borderline tumour. Diagnosis is made by imaging plus surgical pathology. CA-125 or HE4 can help risk assessment but must not be used alone to decide if a mass is benign, borderline, or cancer. annalsofoncology.org+1

A) Physical examination

1. General abdominal exam
   Your clinician looks and feels for swelling, tenderness, a firm mass, or fluid. This helps decide how urgent the case is and which scans to order. RCOG

2. Bimanual pelvic exam
   The doctor gently feels the uterus and ovaries with one hand on the tummy and two fingers in the vagina. They assess size, shape, and mobility of the mass. A fixed, nodular mass is more worrisome. RCOG

3. Speculum exam
   Checks the cervix and vagina for bleeding, discharge, or lesions. It does not diagnose an ovarian mass but rules out other causes of symptoms. RCOG

4. Rectovaginal exam (when needed)
   Gives extra detail about tissue behind the uterus and the rectum, where endometriosis nodules or implants can hide. RCOG

5. Assessment for ascites and hernias
   Looking for free fluid and for hernias that could explain swelling. RCOG

B) “Manual” office tests and bedside assessments

6. Pain mapping and mobility test of the mass
   Gentle pressure checks whether the mass moves freely or is stuck. Mobility often points toward a benign or borderline process; fixation raises concern. RCOG

7. Pregnancy test (urine, point-of-care)
   Always done in people who could be pregnant. Pregnancy changes management and helps rule out conditions like ectopic pregnancy. RCOG

8. Risk scoring at bedside (history + exam)
   Simple scores (e.g., “benign features” vs “worrying features”) guide referral to a gynaecologic oncologist. These scores always get confirmed with imaging and labs. RCOG

C) Laboratory and pathological tests

9. Serum CA-125
   Higher levels can appear with many conditions, including benign ones. Helpful in postmenopausal patients and when combined with imaging, but not a stand-alone test to label a mass as benign, borderline, or malignant. annalsofoncology.org

10. Serum HE4
    Another marker used with CA-125 in some risk models. Like CA-125, it should not be used on its own to decide tumour type. annalsofoncology.org

11. ROMA (Risk of Ovarian Malignancy Algorithm)
    Uses CA-125 and HE4 plus menopausal status to stratify risk and guide referral. It does not tell you “borderline vs cancer.” annalsofoncology.org

12. CEA and CA19-9 (especially for mucinous masses)
    Mucinous tumours, including mucinous BOTs, can raise these markers. CEA also helps check for a gastrointestinal source when the picture is unclear. PMC

13. CBC and chemistry panel
    Looks for anaemia, infection, or kidney/liver issues before surgery. Helpful for safe planning. RCOG

14. Pregnancy test (serum β-hCG)
    If urine testing is unclear, a lab blood test confirms. This is vital before imaging with contrast or surgery. RCOG

15. Intra-operative frozen section
    During surgery, the pathologist gives a rapid, same-day read to guide how much surgery is needed. Final diagnosis still depends on full, permanent sections later. Cancer.gov

16. Final surgical pathology with WHO criteria
    This is the gold standard. The pathologist studies multiple tissue samples from the ovary and from staging biopsies. They confirm “borderline” features (proliferation and atypia without invasion). Subtype is also assigned. ICCR

D) Electrodiagnostic tests

Electrodiagnostic studies (like EMG or nerve conduction) are not used to diagnose ovarian masses. They do not help with borderline tumours. If done, they are for other health issues. This category is therefore not applicable for BOT diagnosis. PubMed

E) Imaging tests

17. Transvaginal ultrasound (TVUS)
    First-line test. It shows cyst walls, septa, papillary projections, and blood flow. Borderline tumours often look like complex cysts with fine internal outgrowths. Expert ultrasound strongly improves accuracy. RCOG

18. Doppler ultrasound
    Measures blood flow inside solid parts. It adds detail to the grayscale scan but cannot by itself label a mass as borderline. RCOG

19. Standardised ultrasound scoring (IOTA / O-RADS)
    Structured rules help classify risk and guide referral. They improve consistency, especially for non-experts. RCOG

20. MRI of the pelvis
    Used when ultrasound is unclear. MRI shows wall thickness, nodules, and haemorrhage and helps plan surgery while protecting fertility when possible. AJR Online

21. CT of abdomen and pelvis (with contrast if safe)
    Used for surgical planning and to look for implants or lymph nodes when risk seems higher. CT is also used if tumour markers or symptoms suggest spread. Cancer.gov

22. Chest imaging (X-ray or CT)
    Done when fluid on the lungs or advanced disease is suspected. Cancer.gov

23. PET-CT (selected cases)
    Not routine for every ovarian mass. It may help in complex cases after MDT (multi-disciplinary) review. Cancer.gov

Non-pharmacological treatments (therapies and others)

1) Expert gynecologic oncology surgery and staging
Surgery is the cornerstone of BOT care. The goals are to remove the tumor, inspect the abdomen/pelvis, sample the omentum and peritoneum as needed, and preserve fertility when appropriate. For early-stage disease, many people do well with fertility-sparing options (removal of the involved ovary and tube) plus careful follow-up. Advanced BOT should be managed by specialists experienced in peritoneal implants and meticulous debulking. Clear communication about childbearing plans is essential before surgery. Cancer.gov+2Cancer.gov+2

2) Fertility-sparing surgery with counseling
In appropriate early cases, surgeons may remove only the affected ovary and tube (unilateral salpingo-oophorectomy) or perform a cystectomy, aiming to retain the uterus and the other ovary. This strategy balances oncologic safety with future pregnancy plans. Recurrence risk after cystectomy can be higher than after oophorectomy, so surveillance is vital and completion surgery may be discussed after childbearing. PMC+1

3) Completion surgery after childbearing
Some patients who choose fertility-sparing surgery later consider “completion surgery” to lower recurrence risk (removal of the remaining ovary ± uterus, with staging/omentectomy as indicated). The decision is individualized based on pathology (e.g., implants, micropapillary pattern), age, and preferences. Cancer.gov

4) Structured surveillance (“watchful follow-up”)
Because prognosis is excellent and many recurrences are indolent, scheduled follow-ups are crucial—typically pelvic exams, symptom review, and imaging as clinically indicated. Long-term surveillance is recommended since late recurrences can occur. Cancer.gov+1

5) Pathology review by an experienced gynecologic pathologist
BOT subtypes (e.g., serous, mucinous) and features such as microinvasion or implants influence management and follow-up. Expert review reduces misclassification and guides tailored surgical plans. PMC

6) Pre-surgical and survivorship nutrition counseling
Eating a plant-forward, fiber-rich diet with adequate protein supports recovery, weight stability, and energy. After treatment, general oncology guidelines promote whole grains, fruits/vegetables, and limited added sugars/alcohol to support long-term health. PubMed+1

7) Exercise therapy (aerobic + strength)
Regular physical activity improves fatigue, mood, and overall function during survivorship. General cancer guidance recommends 150–300 minutes of moderate activity weekly plus strength training to preserve muscle and bone health. Start gradually and build safely after surgery. American Cancer Society

8) Pelvic floor physical therapy
After pelvic surgery, some people experience pelvic pain, scar tightness, or sexual discomfort. Pelvic floor PT can use gentle manual therapy, stretching, relaxation, and education to restore mobility and comfort. It complements gynecologic care and improves quality of life. Canadian Cancer Society

9) Mind-body therapies for pain and stress
Evidence-based integrative approaches—such as mindfulness, relaxation, and acupuncture—can help with cancer-related pain and anxiety. They are safe adjuncts when delivered by qualified practitioners and coordinated with medical care. cancercentrum.se

10) Sexual health counseling
Discomfort, body-image concerns, or vaginal dryness may follow pelvic surgery. Early counseling, lubricants/moisturizers, pelvic floor therapy, and, when appropriate, gynecologic evaluation (e.g., for hypoestrogenism) can restore comfort and intimacy. Canadian Cancer Society

11) Symptom-directed psychosocial support
Distress, fear of recurrence, and decision stress are common. Brief counseling, peer groups, and stepped-care mental health support reduce anxiety and improve coping across survivorship. Cancer.gov

12) Genetic risk evaluation when history suggests it
BOTs are less strongly linked to BRCA than invasive cancers, but a strong family history of breast/ovarian cancer warrants genetic counseling/testing. Results can influence preventive choices for patients and relatives. JNCCN

13) Prehabilitation before surgery
Short programs combining walking, breathing exercises, nutrition optimization, and smoking cessation can improve surgical recovery, reduce complications, and shorten time to baseline function. PubMed

14) Smoking and alcohol reduction
Avoiding tobacco supports wound healing and long-term health; limiting alcohol aligns with cancer survivorship guidance. Behavioral programs and brief counseling are effective. PubMed

15) Sleep hygiene coaching
Structured routines, light exposure, and stimulus control strategies improve sleep after surgery and during survivorship; better sleep supports mood and immune function. PMC

16) Nausea self-care strategies
Small frequent meals, bland foods, ginger preparations, and hydration can ease postoperative or treatment-related nausea. Ginger’s evidence in chemotherapy nausea is mixed; use as a gentle adjunct if desired. PubMed+1

17) Bowel regimen and adhesions education
After pelvic surgery, constipation and adhesions can cause discomfort. Fiber, fluids, gentle activity, and a simple bowel plan help regularity; seek care for persistent pain, vomiting, or obstruction signs. Cancer.gov

18) Return-to-work and activity planning
Graduated activity plans and workplace adjustments (lifting limits, flexible hours) ease the transition back to normal routines and reduce fatigue. PMC

19) Vaccinations and preventive care
Staying current with routine vaccines and preventive screenings supports overall health throughout survivorship; coordinate timing with your gynecologic team. PubMed

20) Long-term survivorship care plan
A written plan summarizes surgery details, pathology, follow-up schedule, warning symptoms, lifestyle guidance, and contacts. It improves coordination among clinicians over years of follow-up. annalsofoncology.org

---

Drug treatments

Critical context: No drugs are approved specifically for BOT. When BOT behaves like epithelial ovarian cancer, clinicians may borrow (off-label) from ovarian cancer regimens. Below I list commonly used ovarian cancer drugs (for context) plus key supportive medicines. Always follow your specialist’s advice.

1) Paclitaxel (Taxol) – cytotoxic chemotherapy
Use & purpose: Standard first-line component for epithelial ovarian cancer in combination with platinum; not routine for BOT, but may be considered if disease transforms or behaves invasively. Class: Taxane. Typical dosing/time: 175 mg/m² IV over 3 h every 3 weeks with platinum (varies). Mechanism: Stabilizes microtubules, blocking cell division. Side effects: Neuropathy, myelosuppression, alopecia, hypersensitivity; premedication reduces reactions. Evidence & labeling are for ovarian carcinoma. FDA Access Data+1

2) Carboplatin (Paraplatin) – cytotoxic chemotherapy
Use: Paired with paclitaxel for ovarian cancer; not standard for BOT unless unusual circumstances. Class: Platinum. Dose: AUC-based (e.g., AUC 5–6) IV every 3 weeks. Mechanism: DNA cross-linking → apoptosis. Side effects: Myelosuppression (notably thrombocytopenia), nausea, neuropathy (less than cisplatin). Labeling documents ovarian cancer indication. FDA Access Data+1

3) Bevacizumab (Avastin) – anti-VEGF monoclonal antibody
Use: Approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination and as maintenance; not BOT-specific. Dose: Often 15 mg/kg IV q3wk with chemotherapy, then maintenance. Mechanism: Inhibits angiogenesis by binding VEGF-A. Key risks: Hypertension, proteinuria, bleeding, GI perforation; avoid near major surgery. FDA Access Data+1

4) Olaparib (Lynparza) – PARP inhibitor (targeted therapy)
Use: Maintenance for recurrent ovarian cancer responding to platinum; some first-line maintenance combinations in HRD-positive disease; not BOT-specific. Dose: Commonly 300 mg PO twice daily (tablet), per label. Mechanism: PARP inhibition exploits homologous recombination defects. Side effects: Fatigue, anemia, nausea; monitor CBC. FDA Access Data+1

5) Niraparib (Zejula) – PARP inhibitor
Use: Maintenance therapy in advanced or recurrent epithelial ovarian cancer after platinum response; not BOT-specific. Dose: 300 mg PO once daily, with dose adjustments for weight/platelets in some protocols. Side effects: Thrombocytopenia, anemia, hypertension; regular monitoring needed. FDA Access Data+1

6) Cisplatin – cytotoxic chemotherapy
Use: Historical/alternative platinum for ovarian carcinoma; rarely relevant to BOT. Mechanism: DNA crosslinks; Side effects: Nephrotoxicity, neurotoxicity, nausea, ototoxicity; requires hydration and antiemetics. (Evidence and labeling are for ovarian carcinoma regimens; cisplatin is part of older paclitaxel/cisplatin data.) FDA Access Data

7) Antiemetics (e.g., Ondansetron)
Use: Control nausea with surgery or chemotherapy. Class: 5-HT3 antagonist. Dose: Commonly 8 mg PO/IV before emetogenic therapy then scheduled; Mechanism: Blocks serotonin receptors in the gut/brain. Side effects: Headache, constipation, QT prolongation. (Labeling supports chemotherapy/postoperative nausea control.) FDA Access Data

8) Aprepitant (± dexamethasone) – NK1 antagonist antiemetic
Use: Add-on for highly emetogenic regimens (if chemotherapy ever used). Dose: Per label (e.g., 125 mg day 1, then 80 mg days 2–3). Mechanism: Blocks substance P/neurokinin-1 pathways. Side effects: Hiccups, fatigue, interactions; coordinate with oncology. (Label evidence for CINV; included here for completeness when ovarian-cancer–style chemo is used.) FDA Access Data

9) Pain control (e.g., acetaminophen, short NSAID course if appropriate)
Use: Post-surgical pain, pelvic discomfort. Mechanism: Central COX inhibition (acetaminophen), peripheral COX inhibition (NSAIDs). Risks: Respect liver/renal cautions and bleeding risk; coordinate with surgeon. (General supportive care within oncology guidelines.) PubMed

10) Growth-factor support when chemotherapy is used (see regenerative section)
Use: Reduce febrile neutropenia with myelosuppressive chemotherapy. Agents: Filgrastim or pegfilgrastim. Risks: Bone pain, rare splenic rupture; timed dosing around chemo. (Labeled for chemotherapy-induced neutropenia in non-myeloid malignancies.) FDA Access Data+1

---

Dietary molecular supplements

Always discuss supplements with your clinician to avoid interactions. Evidence below is general to oncology survivorship/symptoms, not BOT-specific.

1) Vitamin D
Many adults have low vitamin D. Adequate levels support bone and muscle health, which matters after pelvic surgery and through menopause. Typical maintenance dosing ranges 600–800 IU/day, with higher individualized doses if deficient; avoid excess to prevent hypercalcemia. The NIH fact sheet summarizes benefits, safe upper limits, and interaction cautions. Office of Dietary Supplements

2) Omega-3 fatty acids (EPA/DHA)
Omega-3s support cardiometabolic health and may help inflammation and some symptoms like cancer-related fatigue in selected contexts. Dietary sources (fish) are preferred; supplements often 1–2 g/day combined EPA/DHA when advised. Watch for bleeding risk at higher doses or with anticoagulants. Office of Dietary Supplements

3) Ginger (Zingiber officinale)
Ginger is widely used for nausea. Evidence is mixed—some reviews find benefit for vomiting/fatigue; others are neutral—so consider it as a gentle adjunct (e.g., capsules/tea or crystallized ginger) alongside standard antiemetics. Typical study doses range 0.5–1 g/day. PubMed+1

4) Probiotics
Select strains may help bowel regularity after surgery and antibiotic use. Choose reputable products and monitor for gas/bloating. Immunocompromised patients should seek medical advice first. (Data primarily from general surgical/oncology settings.) PubMed

5) Magnesium (if low)
Supports muscle and nerve function, bowel regularity, and sleep quality. Doses vary by formulation (e.g., 200–400 mg elemental/day); excessive amounts can cause diarrhea—dose cautiously. PubMed

6) Protein supplementation (whey/plant blends)
If appetite is low after surgery, adding 20–30 g high-quality protein to meals helps preserve lean mass and healing; prioritize food first, and use shakes when needed. PubMed

7) Calcium (diet-first; supplements only if needed)
Protects bone when ovarian function changes after surgery. Meet needs primarily via food; supplement only to fill a gap and avoid excess. Pair with vitamin D per clinician guidance. Office of Dietary Supplements

8) Fiber (psyllium/inulin) as foods or targeted supplement
Gradual fiber increase with fluids supports regularity and colon health after pelvic surgery; start low to reduce gas/bloating. PubMed

9) Green-tea catechins (EGCG) – caution
Green tea is generally safe as a beverage; concentrated extracts can interact with drugs and affect liver enzymes. If used, keep to modest doses and disclose to your team. PubMed

10) Multivitamin at RDA levels (if diet is limited)
A simple once-daily multivitamin can cover small gaps during recovery. Avoid high-dose antioxidant “megadoses,” which may interact with treatments if chemotherapy is ever used. PubMed

---

Immunity-booster / regenerative / stem-cell–related” drugs

These medicines do not treat BOT; they support blood counts if ovarian-cancer–style chemotherapy is used or address treatment-related cytopenias. Use only under oncology guidance.

1) Filgrastim (Neupogen)
Short-acting G-CSF to raise neutrophils and cut risk of febrile neutropenia during myelosuppressive chemo; daily dosing starting ≥24 h after chemo. Watch for bone pain and rare splenic rupture. FDA Access Data

2) Pegfilgrastim (Neulasta)
Long-acting G-CSF given once per chemo cycle to reduce febrile neutropenia. On-body injector options exist; same class effects/cautions as filgrastim. FDA Access Data

3) Epoetin alfa (Procrit/Epogen)
Stimulates red-cell production for chemotherapy-induced anemia in select circumstances; careful risk-benefit discussion required due to thrombotic risks and disease-outcome considerations. FDA Access Data+1

4) Romiplostim (Nplate)
Thrombopoietin-receptor agonist to raise platelets in chronic ITP; occasionally considered off-label in complex chemo-related thrombocytopenia, under hematology oversight. Risks include marrow reticulin changes. FDA Access Data+1

5) Eltrombopag (Promacta)
Oral thrombopoietin-receptor agonist for thrombocytopenia in specific labeled settings; monitor for hepatotoxicity and interactions (chelation with polyvalent cations). FDA Access Data+1

6) Autologous stem-cell support (conceptual, not typical for BOT)
High-dose chemotherapy with stem-cell rescue is not a BOT strategy; noted here only to clarify that blood-forming growth factors are preferred if chemotherapy is ever needed. Decisions require specialized centers. Cancer.gov

---

Surgeries (what they are and why they’re done)

1) Unilateral salpingo-oophorectomy (USO)
Removal of one ovary and fallopian tube containing the BOT, often with staging biopsies and omentectomy as indicated. Chosen to preserve fertility in early-stage, unilateral disease. Cancer.gov+1

2) Cystectomy (ovarian cyst removal)
Shelling out the tumor while preserving ovarian tissue. Considered in highly selected patients; recurrence risk can be higher than USO, so surveillance is essential. PMC

3) Bilateral salpingo-oophorectomy (BSO)
Removal of both ovaries and tubes, typically when childbearing is complete, when disease is bilateral, or in recurrent settings; reduces recurrence risk. Cancer.gov

4) Omentectomy and peritoneal staging
Inspection and sampling of the omentum and peritoneal surfaces help determine spread and guide follow-up, particularly for serous BOT with implants. Cancer.gov

5) Completion surgery after fertility
For those initially treated with fertility-sparing approaches, later removal of remaining at-risk tissue can be considered to reduce late recurrence. Cancer.gov

---

Prevention pointers

1. Oral contraceptive pill (OCP) use reduces epithelial ovarian cancer risk—risk falls ~30–50% overall and protection increases with duration; benefit persists years after stopping. (Whether this applies identically to BOT is less certain, but trend is protective.) Cancer.gov

2. Opportunistic salpingectomy (removing fallopian tubes during other pelvic surgery) is endorsed by ACOG to reduce epithelial ovarian cancer risk for average-risk women already having gynecologic surgery. ACOG+1

3. Parity and breastfeeding are associated with lower epithelial ovarian cancer risk at a population level. Nature

4. Regular physical activity supports healthy weight and overall survivorship health. American Cancer Society

5. Avoid tobacco to support surgical recovery and general cancer prevention. PubMed

6. Limit alcohol within survivorship guidelines. PubMed

7. Know your family history and seek genetic counseling if there are multiple breast/ovarian cancers in relatives. JNCCN

8. Timely gynecologic evaluation of new pelvic symptoms enables earlier detection of masses. Cancer.gov

9. Healthy diet pattern (plant-forward, fiber-rich, low in added sugars) supports weight and metabolic health. PubMed

10. Keep up with routine preventive care (vaccines, screenings) to maintain overall health. PubMed

---

When to see a doctor

Seek prompt gynecologic care for new or persistent pelvic/abdominal pain, bloating, feeling full quickly, pelvic pressure, urinary urgency, or unexplained changes in periods or weight. If you’ve had BOT surgery, report any new symptoms, a growing mass, or changes on imaging. Long-term, keep scheduled follow-ups because late recurrences can occur even many years after initial treatment. Cancer.gov+1

---

What to eat and what to avoid

Eat mostly whole plant foods—vegetables, fruits, legumes, whole grains, nuts—and include adequate protein (fish, eggs, dairy or soy/legumes) to support recovery and lean mass. Use healthy fats (olive oil, nuts) and drink plenty of water. Limit highly processed foods, sugary drinks, and excess alcohol; these do not help recovery and may worsen fatigue and weight changes. If appetite is low, try small frequent meals and consider a short-term protein shake to meet needs. Always individualize if you have bowel or metabolic issues. PubMed+1

---

Frequently asked questions (FAQs)

1) Is a borderline tumor cancer?
No. By definition, BOT cells look atypical and proliferative but do not invade nearby tissue. That’s why prognosis is much better than invasive ovarian cancer. Cancer.gov

2) What treatment cures most BOTs?
Surgery is usually curative, especially in early stages. Many people need no chemotherapy. Cancer.gov

3) Can I keep my fertility?
Often yes. Many early-stage cases can be managed with fertility-sparing surgery and close follow-up; some opt for completion surgery after childbearing. ecancer

4) What are “implants,” and do they change treatment?
Peritoneal implants are tumor deposits in the abdomen. Their type (noninvasive vs invasive) influences prognosis and surgical planning; invasive implants may prompt more aggressive management. PMC

5) Do I need chemotherapy?
Usually no for BOT. Chemo is considered only in exceptional situations (e.g., malignant transformation). Cancer.gov

6) How often is follow-up?
Schedules vary, but long-term follow-up is advised because late recurrences can occur. Your team will tailor visit frequency and imaging. annalsofoncology.org

7) What is my long-term outlook?
Excellent overall: many series show >90% survival at 10–20 years, especially when diagnosed early. Cancer.gov

8) Can lifestyle help?
Yes—regular activity, plant-forward eating, not smoking, and healthy weight support overall wellbeing and recovery. American Cancer Society+1

9) Should I take supplements?
Food first. Consider vitamin D if low, omega-3s if diet lacks fish, and gentle options like ginger for nausea—with clinician guidance to avoid interactions. Office of Dietary Supplements+2Office of Dietary Supplements+2

10) Will surgery push me into menopause?
Removing both ovaries causes surgical menopause. With one ovary preserved, many keep hormonal function; discuss symptoms and options with your team. Cancer.gov

11) Is BOT genetic?
Most cases are not clearly inherited. However, strong family histories should trigger genetic counseling and possibly testing. JNCCN

12) What if I become pregnant after BOT?
Many successfully conceive after fertility-sparing surgery. Your obstetric and oncology teams will coordinate follow-up during pregnancy. ecancer

13) Are PARP inhibitors for me?
PARP inhibitors (like olaparib, niraparib) are approved for epithelial ovarian cancer, not specifically BOT; they would be considered only if disease behaves like carcinoma. FDA Access Data+1

14) Does the pill lower my risk?
Population studies show OCPs reduce epithelial ovarian cancer risk by ~30–50%; whether BOT risk falls to the same degree is less certain, but trend is protective. Cancer.gov

15) What warning signs after surgery deserve urgent care?
Fever, worsening abdominal pain, persistent vomiting, inability to pass stool/gas, rapid abdominal swelling, or wound issues—contact your team immediately. Cancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.